Nektar Therapeutics (NKTR) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $2.03B is the value of all shares combined. Beta 1.18: the stock has moved about 18% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNektar Therapeutics (NKTR) trades at $70.65 with MoonshotScore 23/100 (Grade F). Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines for unmet medical needs. Market cap: $2.03B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: May 9, 2026NKTR stock analysis for 2026: Analysts have set a consensus price target of $150.00 for Nektar Therapeutics, suggesting 112.3% upside from the current price of $70.65. The AI MoonshotScore is 23/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
These figures come from statements filed 12 months ago — the most recent this company has published.
NKTR: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Momentum (7/10, Moderate). Weakest side: Growth Durability (2/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Nektar Therapeutics (NKTR) Healthcare & Pipeline Overview
Nektar Therapeutics is a biopharmaceutical company focusing on discovering and developing novel medicines, particularly in immuno-oncology and autoimmune diseases. With a pipeline of clinical-stage assets and strategic collaborations, Nektar aims to address unmet medical needs through innovative therapies and partnerships within the competitive biotechnology landscape.
What Is the Investment Thesis for NKTR?
Key value drivers include the potential success of Bempegaldesleukin in ongoing Phase 3 trials for various cancer indications, with results expected to influence valuation significantly. The development of NKTR-358 for autoimmune diseases represents another growth catalyst, addressing a substantial market with limited treatment options. Strategic collaborations with major pharmaceutical companies provide financial resources and validation of Nektar's technology. However, risks include clinical trial failures, regulatory hurdles, and competition from established players in the biotechnology sector. The company's high gross margin of 80.1% suggests strong potential profitability if its key drug candidates achieve regulatory approval and commercial success. Investors should closely monitor clinical trial outcomes and partnership developments to assess the long-term value of Nektar Therapeutics.
Based on FMP financials and quantitative analysis
NKTR Key Highlights
Market Cap of $2.03B reflects investor sentiment regarding Nektar's pipeline and potential for future growth.
- Gross Margin of 80.1% indicates a strong ability to generate profit from its products and collaborations.
- Profit Margin of -284.2% highlights the significant investment in research and development typical of biotechnology companies in the clinical stage.
- Beta of 1.18 suggests that the stock is slightly more volatile than the overall market.
- No dividend is currently offered, which is common for growth-oriented biopharmaceutical companies reinvesting earnings into research and development.
Who Are NKTR's Competitors?
NKTR is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $63.75 | -1.02% | $130B | 905-pillar |
| MRK Merck & Co., Inc. | $144.71 | -1.91% | $357B | 745-pillar |
| AZN AstraZeneca PLC | $157.88 | +0.60% | $245B | 855-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NKTR's Key Strengths?
Innovative pipeline of clinical-stage drug candidates.
- Proprietary polymer technology enhances drug efficacy.
- Strategic collaborations with major pharmaceutical companies.
- Experienced management team with expertise in drug development.
What Are NKTR's Weaknesses?
High R&D spending and negative profit margins.
- Reliance on clinical trial success and regulatory approvals.
- Competition from established pharmaceutical companies.
- Limited commercialized products and revenue streams.
What Could Drive NKTR Stock Higher?
Clinical trial results for Bempegaldesleukin in metastatic melanoma (2026-2027).
- Clinical trial results for NKTR-358 in systemic lupus erythematosus (2026-2027).
- Advancement of NKTR-255 through Phase 1/2 clinical trials for hematological malignancies and solid tumors.
- Expansion of strategic collaborations with pharmaceutical companies to co-develop and commercialize drug candidates.
What Are the Key Risks for NKTR?
Negative return on equity (-38.0%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for key drug candidates.
- Regulatory setbacks and delays in drug approvals.
- Competition from established pharmaceutical companies and biosimilars.
- High R&D spending and negative profit margins.
- Changes in healthcare regulations and reimbursement policies.
What Are the Growth Opportunities for NKTR?
- Expansion of Bempegaldesleukin into new cancer indications: Bempegaldesleukin, Nektar's lead drug candidate, has the potential to expand beyond its current clinical trials into additional cancer types.
- Development of NKTR-358 for autoimmune diseases: NKTR-358, a cytokine Treg stimulant, targets autoimmune diseases such as systemic lupus erythematosus and ulcerative colitis. The autoimmune disease therapeutics market is estimated to reach $63.8 billion by 2027, driven by increasing prevalence and demand for novel therapies. Successful clinical trials and regulatory approval could position NKTR-358 as a key player in this market within the next 5-7 years.
- Advancement of NKTR-255 for hematological malignancies and solid tumors: NKTR-255, an IL-15 receptor agonist, is being developed for hematological malignancies and solid tumors. The global oncology market is projected to reach $286.6 billion by 2030, offering a substantial opportunity for Nektar to address unmet needs in these areas. Clinical trial progress and strategic partnerships will be crucial for realizing this growth potential over the next 5-7 years.
- Strategic collaborations with pharmaceutical companies: Nektar's collaboration agreements with major pharmaceutical companies provide financial resources and validation of its technology platform. Expanding these partnerships and securing new collaborations can accelerate the development and commercialization of its drug candidates. The pharmaceutical industry is increasingly focused on external innovation, creating opportunities for Nektar to leverage its expertise and pipeline.
- Leveraging proprietary polymer technology: Nektar's proprietary polymer technology enhances the efficacy and safety of existing or novel drug candidates. This technology can be applied to a wide range of therapeutic areas, providing a competitive advantage and opportunities for developing new products. Continued innovation and application of this technology will be crucial for sustaining long-term growth and differentiation in the biotechnology market.
What Are NKTR's Competitive Advantages?
- Proprietary polymer technology enhances drug efficacy and safety.
- Strong intellectual property portfolio protects drug candidates.
- Strategic collaborations with major pharmaceutical companies provide financial resources and validation.
- Clinical-stage pipeline with multiple drug candidates addressing unmet medical needs.
What Does NKTR Do?
Nektar Therapeutics, founded in 1990 and headquartered in San Francisco, California, is a biopharmaceutical company dedicated to discovering and developing innovative medicines for areas of high unmet medical need. The company focuses primarily on immuno-oncology, autoimmune diseases, and other therapeutic areas where its proprietary polymer technology can enhance the efficacy and safety of existing or novel drug candidates. Nektar's lead product candidate, Bempegaldesleukin, is a CD122-preferential interleukin-2 (IL-2) pathway agonist that has been in various clinical trials, including Phase 3 studies for metastatic melanoma, renal cell carcinoma, and other cancers. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant for autoimmune diseases like systemic lupus erythematosus and ulcerative colitis, and NKTR-255, an IL-15 receptor agonist for hematological malignancies and solid tumors. Nektar has established numerous collaborations with major pharmaceutical companies, including Takeda, AstraZeneca, UCB Pharma, Roche, Bausch Health, Pfizer, Amgen, Bristol-Myers Squibb, and others, to advance its pipeline and leverage its technology platform. These partnerships are crucial for funding research and development efforts and expanding the potential applications of Nektar's drug candidates. Nektar continues to focus on advancing its clinical programs and exploring new opportunities to address significant medical challenges.
What Products and Services Does NKTR Offer?
- Discovers and develops innovative medicines.
- Focuses on areas of unmet medical need.
- Develops therapies for cancer and autoimmune diseases.
- Utilizes proprietary polymer technology to enhance drug efficacy.
- Conducts clinical trials to evaluate drug candidates.
- Collaborates with major pharmaceutical companies to advance its pipeline.
How Does NKTR Make Money?
- Develops and patents novel drug candidates.
- Conducts clinical trials to demonstrate safety and efficacy.
- Out-licenses or co-develops drug candidates with pharmaceutical partners.
- Generates revenue through collaboration agreements, milestone payments, and royalties.
What Industry Does NKTR Operate In?
Nektar Therapeutics operates within the competitive biotechnology industry, characterized by high R&D spending, stringent regulatory requirements, and intense competition. The immuno-oncology and autoimmune disease markets are experiencing significant growth, driven by increasing prevalence and unmet medical needs. Key trends include the development of novel immunotherapies, personalized medicine approaches, and combination therapies. Nektar's success depends on its ability to differentiate its drug candidates through enhanced efficacy, improved safety profiles, and strategic partnerships. Competition includes established pharmaceutical companies and other biotechnology firms developing similar therapies.
Who Are NKTR's Key Customers?
- Patients with cancer and autoimmune diseases.
- Pharmaceutical companies seeking innovative drug candidates.
- Healthcare providers prescribing Nektar's therapies.
- Research institutions collaborating on drug development.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 91% of our measures
- ● Price is current
- ● Latest filing 28 days ago
- ● Covered by analysts
Why 23?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.43 Short-term liquidity (Financial Strength)
- +0.31 Gross margin (Business Quality)
- +0.11 5-year net income per share (Growth)
What is holding it back
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
- -0.48 Revenue growth (Growth)
Risk penalties applied
- -0.00 Bankruptcy-risk score in the grey zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
Nektar Therapeutics (NKTR) Valuation Context
Valued at $2.03B, NKTR is classified as a mid-cap stock. Relative to its peer group, NKTR's quantitative score of 23/100 is below the peer average of 83/100.
NKTR Revenue & Earnings Trend
In Q2 FY2026, NKTR generated $10.1M in top-line revenue, marking a sequential decrease of 6.7%. The company recorded a net loss of $40.6M, with diluted EPS of $-1.23. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, NKTR averaged $-1.84 in diluted EPS.
Company Profile
Nektar Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, United States.
Key Financial Metrics
Return on equity for Nektar Therapeutics stands at -38.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.6%, the inverse of the P/E and a quick read on earnings relative to price.
NKTR Financials
Bull Case vs Bear Case
Bull Case
- Innovative pipeline of clinical-stage drug candidates.
- Proprietary polymer technology enhances drug efficacy.
- Strategic collaborations with major pharmaceutical companies.
- Experienced management team with expertise in drug development.
Bear Case
- High R&D spending and negative profit margins.
- Reliance on clinical trial success and regulatory approvals.
- Competition from established pharmaceutical companies.
- Limited commercialized products and revenue streams.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $10M | -$41M | -$1.23 |
| Q1 FY2026 | $11M | -$45M | -$1.82 |
| Q4 FY2025 | $22M | -$36M | -$1.78 |
| Q3 FY2025 | $12M | -$36M | -$2.52 |
Q2 FY2026 · filed 14 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
NKTR Latest News
No recent news available for NKTR.
NKTR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NKTR.
Price Targets
Consensus target: $150.00
NKTR MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. NKTR scores 23/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Leadership: Howard W. Robin
CEO
Howard W. Robin has served as the Chief Executive Officer of Nektar Therapeutics, managing 61 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Nektar, he held leadership positions at various companies, focusing on strategic planning, business development, and commercial operations. His expertise spans across multiple therapeutic areas, including oncology, immunology, and infectious diseases. Robin's experience also includes roles in finance and investment banking, providing a broad perspective on the biopharmaceutical industry.
Track Record: Under Howard W. Robin's leadership, Nektar Therapeutics has focused on advancing its clinical-stage pipeline and securing strategic collaborations with major pharmaceutical companies. Key achievements include the progression of Bempegaldesleukin through Phase 3 clinical trials and the development of NKTR-358 for autoimmune diseases. Robin has also overseen the expansion of Nektar's technology platform and the strengthening of its intellectual property portfolio.
What Investors Ask About Nektar Therapeutics (NKTR) — Healthcare
What does the AI Score mean for NKTR?
NKTR holds an AI Score of 23/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines for unmet medical needs.
Is NKTR a good stock?
Stock Expert AI does not rate NKTR buy, sell or hold. Nektar Therapeutics carries a MoonshotScore of 23/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for NKTR?
Nektar Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of its drug candidates depends on positive clinical data and regulatory approvals. High R&D spending and negative profit margins create financial challenges.
What are the key factors to evaluate for NKTR?
Nektar Therapeutics (NKTR) holds an AI score of 23/100 (low). Analysts target $150.00 (+112%). Market Cap of $2.03B reflects investor sentiment regarding Nektar's pipeline and potential for future growth. Not financial advice.
How frequently does NKTR data refresh on this page?
NKTR's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NKTR's recent stock price performance?
Nektar Therapeutics (NKTR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of clinical-stage drug candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NKTR overvalued or undervalued right now?
Nektar Therapeutics (NKTR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $150.00 (+112%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NKTR?
Yes, most major brokerages offer fractional shares of Nektar Therapeutics (NKTR) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NKTR's earnings and financial reports?
Nektar Therapeutics (NKTR) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for NKTR earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are uncertain and may impact future performance.